|
About osteoarthritis
|
|
| Home | Smart Ideas | Newsletter / Articles | Site Index |
|
|
|||
|
|
||
Celadrin for Proven Pain ReliefBy Mike Law | Date Submitted: 08/10/05
Category: Life:Health/Nutrition/Fitness The graying of America is leading to dramatic increases in conditions such as osteoarthritis, as well as simple joint pain. Consumers are turning to medications such as aspirin and nonsteroidal anti-inflammatories (NSAIDs) and topical anti-inflammatory creams; however, their long-term use may bring serious side effects. Instead, companies are increasingly looking for natural compounds that can provide relief to their customers and give them a foothold in the $22 billion joint health market. One such natural compound is Celadrin®, which is composed of esterified fatty acid carbons (EFACs) and other active synergists. Developed by Imagenetix, it is now marketed worldwide by Proprietary Nutritionals Inc. (PNI). Manufactured in the United States, the compound undergoes a proprietary process to penetrate cell membranes, allowing it to be used both internally and topically. The basis for Celadrin’s efficacy was first published in the Journal of Rheumatology in 2002.1 The placebo-controlled study involved 64 patients with chronic knee osteoarthritis who were given either vegetable oil or Celadrin for 68 days. Patients in the treatment group experienced significant increase in knee flexibility compared to the placebo group. In addition, the Celadrin group showed a trend toward significant improvement in overall function. The core compound used in the oral dose was transitioned into a topical cream. In a 2002 study at the University of Minnesota, researchers documented transit of the cetylated fatty acids into the bloodstream.2 This study showed an oral dose of Celadrin produced appreciable activity in blood collected from rats, and that application of Celadrin in a cream format showed appearance in the blood with significant localization at the site of application. Starting in the summer of 2002, researchers at the University of Connecticut started a double blind, placebo-controlled study to investigate the efficacy of Celadrin on standard quality of life measurements.3 During this study, 40 patients diagnosed with knee osteoarthritis were randomly assigned to receive either Celadrin cream or a placebo cream. Patients were tested on three occasions: at baseline, 30 minutes after initial treatment and after a 30-day treatment of the cream, used twice daily. After 30 minutes and 30 days, the Celadrin recipients showed significant decreases in time for stair climbing ability and “up-and-go” from a chair. In addition, those patients in the Celadrin group had significant increases in their knee range of motion and unilateral reach, and significant improvement in the medial step-down test. The researchers concluded the Celadrin cream was an effective treatment for relieving pain and improving quality of life in patients with knee osteoarthritis. A phase II study has been initiated that involves adding menthol to the Celadrin cream, and expands the patient group to include adults with problems in their elbows or wrists. The findings have been submitted to the Journal of Rheumatology, and show menthol does not negatively impact the core efficacy of Celadrin. In addition, there were similar quality-of-life findings reported in the knee osteoarthritis group, and significant improvements in wrist and elbow patients on measures associated with prolonged endurance and activity. Compared to other products such as glucosamine, Celadrin has much wider applicability. PNI estimates more than 120 million Americans suffer from arthritic conditions such as osteoarthritis or bursitis plus more than 100 other types of arthritis, sports injuries to joints, muscles, tissues and deep tissue. While glucosamine has been shown efficacious in restoring joint function in osteoarthritis, Celadrin’s activity in relieving pain extends to the entire “pain pie.” Pacific Rainbow Inc. in City of Industry, Calif., is the exclusive U.S. distributor of the Celadrin raw material. --------------------------------------------------------- References 1. Hesslink Jr. RL et al. J Rheumatol. 29, 8:1708-12, 2002. 2. Gallaher DD, Gallaher CM, Hesslink Jr. RL. FASEB J. 16, 4:A365, 2002. 3. Kraemer WJ et al. J Rheumatol. 31, 4:767-74, 2004.
support@wealthontap.com
IdeaMarketers - www.ideamarketers.com |
||